Insider Transactions in Q1 2024 at Nurix Therapeutics, Inc. (NRIX)
Insider Transaction List (Q1 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 16
2024
|
Hans Van Houte Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
6,812
-9.07%
|
$68,120
$10.02 P/Share
|
|
Jan 30
2024
|
Christine Ring Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
1,760
-9.17%
|
$12,320
$7.99 P/Share
|
|
Jan 30
2024
|
Christine Ring Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,924
+9.75%
|
-
|
|
Jan 30
2024
|
Gwenn Hansen Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
2,334
-6.03%
|
$16,338
$7.99 P/Share
|
|
Jan 30
2024
|
Gwenn Hansen Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,207
+6.47%
|
-
|
|
Jan 30
2024
|
Hans Van Houte Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,671
-2.18%
|
$11,697
$7.99 P/Share
|
|
Jan 30
2024
|
Hans Van Houte Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,886
+3.13%
|
-
|